Pharmacokinetic Analysis Services
Pharmacokinetics (PK) defines how a drug moves through the body—absorption, distribution, metabolism, and excretion—shaping every decision from dose selection to safety margins in oncology drug development. At Alfa Cytolog, we translate complex PK questions into actionable data, offering end-to-end preclinical pharmacokinetic analysis services tailored to advance your therapeutic programs from lead optimization through IND-enabling toxicology.
Overview of Pharmacokinetic Analysis
Pharmacokinetic analysis examines the time course of drug concentrations in biological matrices, providing quantitative insight into how a therapeutic agent is handled by a living system. The discipline rests on four interconnected pillars: absorption, which governs how much drug enters systemic circulation; distribution, which describes its transit to tissues and organs; metabolism, which encompasses biotransformation into active or inactive metabolites; and excretion, which tracks elimination from the body. Together, these processes determine exposure profiles, half-life, bioavailability, and clearance—parameters that directly inform dosing regimens, formulation strategies, and safety evaluations. In oncology research, where therapeutic windows can be narrow and off-target toxicity is a persistent concern, robust PK characterization is indispensable for identifying candidates with favorable dispositional properties.
Fig 1. PBPK model application domains in FDA-approved new drugs. (Li, Yangkexin, et al., 2025)
Modern PK investigations span both in vitro and in vivo domains. In vitro approaches such as metabolic stability assays, plasma protein binding assessments, and CYP inhibition studies provide early mechanistic understanding without the complexity of whole-animal physiology. In vivo studies in preclinical species—ranging from single-dose pharmacokinetic screens to repeat-dose toxicokinetic evaluations—generate concentration-time data that feed into non-compartmental and compartmental modeling. Advanced bioanalytical platforms, particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS) and ligand-binding assays (LBA), serve as the analytical backbone, enabling sensitive and selective quantification of parent compounds, metabolites, and biologics across diverse matrices including plasma, serum, urine, bile, and tissue homogenates.
Radiopharmaceutical Development: PK Challenges in Tumor Targeting
| PK Consideration |
Key Challenge |
Emerging Solution |
| Rapid renal clearance |
High kidney uptake and fast elimination reduce tumor exposure time |
Albumin-binding domain fusion or co-infusion of blocking agents |
| Short tumor retention |
Limited residence time compromises therapeutic radiation delivery |
Multivalent ligand design and optimized linker chemistry |
| Off-target distribution |
Bone marrow, liver, and spleen accumulation raises toxicity concerns |
Pre-targeting strategies and pretargeted radioimmunotherapy |
| Metabolic instability |
Enzymatic degradation of radiolabeled peptides in plasma |
D-amino acid substitution and metabolic-resistant scaffolds |
| Soluble target competition |
Circulating FAP or similar antigens compete for radioligand binding |
Dual-targeting approaches and biomarker-driven study design |
| Radiation dosimetry |
Variable PK complicates dose estimation in preclinical species |
PBPK modeling combined with image-based dosimetry |
Our Services
Alfa Cytolog delivers integrated preclinical pharmacokinetic analysis services designed to meet the demands of modern oncology drug development. Our capabilities span method development and validation, quantitative bioanalysis, ADME profiling, and toxicokinetic support across multiple preclinical species. Whether your program involves a novel small-molecule kinase inhibitor, an antibody-drug conjugate, or a radiolabeled therapeutic candidate, our team generates high-quality, reproducible PK data that informs critical go/no-go decisions and strengthens your preclinical development package.
Our Pharmacokinetic Analysis Services
Bioanalytical Method Development & Validation
We develop and validate LC-MS/MS and ligand-binding assays tailored to your analyte, matrix, and sensitivity requirements. Our methods are characterized by robust selectivity, accuracy, and precision, supporting both exploratory and GLP-grade preclinical studies.
In Vitro ADME Screening
Early-stage metabolic stability, plasma protein binding, CYP inhibition, and permeability assessments using hepatocytes, microsomes, and transporter assays. These screens help prioritize lead compounds with favorable dispositional profiles before committing to in vivo preclinical studies.
In Vivo Pharmacokinetic Studies
Single-dose and multiple-dose PK evaluations in rodent and non-rodent species, including blood, plasma, urine, bile, and tissue sampling. We design customized sampling schedules and dose routes to capture complete concentration-time profiles for preclinical characterization.
Toxicokinetic (TK) Analysis
Repeat-dose TK support for preclinical safety assessment studies, integrating exposure data with clinical pathology and histopathology findings to establish exposure-toxicity relationships and no-observed-adverse-effect levels in animal models.
Biologics & ADC PK Characterization
Quantification of total antibody, conjugated antibody, and free payload using hybrid LC-MS/MS and ELISA/MSD platforms. We address the unique PK challenges of large molecules in preclinical species, including target-mediated drug disposition and immunogenicity risk assessment.
Metabolite Identification & Profiling
Detection and structural characterization of major metabolites in in vitro and in vivo preclinical matrices, enabling understanding of metabolic pathways, reactive metabolite risk, and species differences in biotransformation.
Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling
Integration of exposure data with efficacy and biomarker endpoints in preclinical tumor models to establish dose-exposure-response relationships. Our modeling efforts support dose selection, regimen optimization, and preclinical development decision-making.
Sample Analysis & Data Reporting
High-throughput sample processing with rigorous quality control, incurred sample reanalysis, and comprehensive data packages including non-compartmental analysis parameters (Cmax, Tmax, AUC, clearance, half-life) and statistical summaries for preclinical study reports.
Workflow of Pharmacokinetic Analysis Services
Our pharmacokinetic analysis workflow is designed for transparency, efficiency, and scientific rigor. Each project begins with a detailed consultation to align study objectives with analytical strategy, followed by phased execution from method establishment through final reporting. The process ensures that every data point is traceable, every assay is fit-for-purpose, and every timeline is met with precision.
1. Study Design & Consultation: We collaborate with your team to define preclinical study objectives, select appropriate species and matrices, design sampling time points, and determine the bioanalytical platform best suited to your compound class and sensitivity requirements.
2. Method Development: Our scientists develop customized LC-MS/MS or LBA methods, optimizing extraction procedures, chromatographic conditions, and detection parameters to achieve the required lower limit of quantification with acceptable selectivity and matrix effect profiles.
3. Method Validation: The developed method undergoes full or partial validation assessing specificity, linearity, accuracy, precision, recovery, stability, and dilution integrity to ensure reliability across the anticipated concentration range and sample handling conditions.
4. In Vivo Study Execution: Dosing and sample collection are performed in preclinical species according to the approved protocol, with stringent chain-of-custody documentation. Biological samples are processed under controlled conditions to preserve analyte integrity from collection through analysis.
5. Bioanalytical Sample Analysis: Samples are analyzed in validated runs with quality control samples bracketing unknowns. Incurred sample reanalysis is conducted to confirm reproducibility, and any deviations are documented with appropriate corrective actions.
6. PK Data Analysis & Modeling: Concentration-time data are processed using non-compartmental analysis to derive key PK parameters. Where appropriate, compartmental modeling or physiologically-based pharmacokinetic (PBPK) approaches are applied to support mechanistic interpretation within preclinical species.
7. Report Generation & Development Support: A comprehensive report summarizing methods, results, statistical analyses, and conclusions is delivered in a format suitable for inclusion in preclinical development packages. Raw data, chromatograms, and audit trails are archived for future reference.
Why Choose Alfa Cytolog?
Selecting the right partner for preclinical pharmacokinetic analysis can determine the trajectory of your drug development program. Alfa Cytolog combines deep scientific expertise with operational flexibility to deliver data you can trust, on timelines that keep your project moving forward.
- Cross-functional scientific team with extensive experience in small molecules, biologics, and radiopharmaceuticals across diverse preclinical therapeutic modalities
- State-of-the-art bioanalytical infrastructure featuring LC-MS/MS, high-resolution mass spectrometry, and multiplex immunoassay platforms for preclinical analysis
- Flexible study designs adapted to your compound, preclinical species, matrix, and development stage without rigid templated approaches
- Rigorous quality systems ensuring data integrity, traceability, and reproducibility from method development through final preclinical report
- Direct access to senior scientists for real-time troubleshooting, protocol optimization, and strategic guidance throughout the preclinical engagement
- Proven track record supporting oncology programs from early discovery through IND-enabling toxicology studies with consistent on-time delivery
- Integrated service model allowing seamless transition from PK analysis to pharmacology, toxicology, and tumor model studies under one preclinical program umbrella
Contact Us
Ready to advance your oncology drug program with precise preclinical pharmacokinetic data? Reach out to us today to discuss your study requirements, and let our team design a tailored PK analysis strategy that aligns with your preclinical development milestones and scientific goals. We look forward to partnering with you on the path from discovery concept to IND-ready data package.
Reference
- Li, Yangkexin, Henry Sun, and Zuoli Zhang. "The evolution and future directions of PBPK modeling in FDA regulatory review." Pharmaceutics 17.11 (2025): 1413.
For research use only. Not intended for any clinical use.
